Table 2– Studies reporting nonparametric summary statistics for nasal nitric oxide in PCD, healthy control and cystic fibrosis groups measured via stationary analyser with velum closure manoeuvre
StudyPCDHealthy controlsCystic fibrosis
Subjects nOutcome nL·min−1Subjects nOutcome nL·min−1Subjects nOutcome nL·min−1
Karadag et al. [6], 199921Median 13.75
(range 0.83–239.8)		60Median 138.3
(range 29–359.3)
Narang et al. [7], 200231Median 15.1
(range 0.8–230)		53Median 179
(range 99.5–359.3)		17Median 122.8
(range 7.8–285)
Horvath et al. [8], 200314Median 13.6
(range 1.3–67.3)		37Median 165.8
(range 80.5–335.8)		20Median 85.8
(range 7.5–249.3)
Santamaria et al. [29], 200814Median 3.3
(IQR 3.3)		14Median 90.1
(IQR 67.2)
Marthin and Nielsen [25], 2011#12Median 15.9
(95% CI 3–162)
Walker et al. [30], 201314Median 8.1
(IQR 4.8–22.8)		18Median 231.6
(IQR 207–265.8)		12Median 150.3
(IQR 135–182.4)
Boon et al. [31], 201438Median 16.8
(IQR 8.1–35.7)		49Median 236.4
(IQR 198.3–295.8)		46Median 109.5
(IQR 75.6–169.5)
Harris et al. [32], 201411Median 12.3
(IQR 7.5–15.9)		15208.2
(IQR 181.2–240)		6Median 139.5
(IQR 99–227.7)

  • PCD: primary ciliary dyskinesia; IQR: interquartile range. #: consecutive referrals.